

CURRICULUM VITAE ET STUDIORUM

Date Prepared: July 2026
Name: Giovanni Roti
Born January 03, 1977
Office Address: University of Parma, Italy
Via Gramsci 14, 43126 Parma, Italy
Work Email: giovanni.roti@unipr.it

EDUCATION

1996	Bachelor of Science Diploma di Maturità Scientifica	B.S. 58/60	Liceo Scientifico L. Spallanzani, Reggio Emilia
2002	Medicine. Laurea Medicina e Chirurgia	M.D. 110/110	University of Parma
2006	Clinical Fellowship Hematology and BMT	50/50 cum lode	University of Perugia, Hematology
2011	Ph.D. Dottorato di Ricerca	Ph.D.	University of Perugia, Hematology
2025	Master's in Healthcare Management and Health Systems And Organizations		Minister of Health

CLINICAL AND SCIENTIFIC TRAINING

1999-2000	MD student	Université "Claude Bernard" Lyon, France. Centre Hospitalier Lyon Sud Hcl-Pierre Benite, Francia
2000-2002	Residency	Hematology and BMT unit, University of Parma
2002-2006	Clinical Fellowship	Hematology and BMT unit, University of Perugia

Research Fellowships

2007-2011	Post-Doctoral Research Fellow	Dana-Farber Cancer Institute/Broad Institute of Harvard/MIT Harvard Medical School
-----------	-------------------------------	---

ACADEMIC POSITION

YEAR	POSITION	DEPARTMENT	INSTITUTION
2026-	Professor Hematology Principal Investigator	Medicine and Surgery, Hematology THEC laboratory	University of Parma
2022-2026	Associate Professor Hematology Principal Investigator	Medicine and Surgery, Hematology THEC laboratory	University of Parma
2020-2022	Assistant Professor Principal Investigator	Medicine and Surgery, Hematology	University of Parma
2019-2020	Research Scientist A.D.R.	Medicine and Surgery, Hematology	University of Parma
2016-2019	Ricercatore T.D.b Principal Investigator	Medicine and Surgery, Hematology	University of Parma

2011-2016	Ricercatore T.D.a	Medicine, Hematology	University of Perugia
2011-2016	Instructor in Pediatrics	Pediatric Oncology	Dana-Farber Cancer Institute Harvard Medical School
2007-2017	Research Associate	Cancer Program	Broad Institute of Harvard and MIT

CLINICAL RESPONSIBILITIES

<u>YEAR</u>	<u>POSITION</u>	<u>DEPARTMENT</u>	<u>INSTITUTION</u>
2023-	Head Hematology and BMT unit	HEM-ONC	University of Parma, Hospital
2023-	Scientific Director NGS Platform	HEM-ONC	University of Parma, Hospital

NATIONAL SCIENTIFIC QUALIFICATION

2019	Clinical Pathology	06/A2	09/09/2019 - 09/09/2028	Associate professor
2021	Hematology	06/D3	31/05/2021 - 31/05/2030	Associate professor
2021	Pediatrics	06/G1	08/06/2021 - 08/06/2030	Associate professor

INTERNATIONAL EXPERIENCES

Post-Doctoral Research Fellow (Laboratory: Kimberly Stegmaier, MD)
Department of Pediatric Oncology.
Leukemia Program (Head: Stuart H. Orkin, MD, PhD; David A. Williams, MD).
Dana-Farber Cancer Institute, Boston, MA, USA.

&
Post-Doctoral Research Fellow
Harvard Medical School. Boston, MA, USA
from 02-01-2007 to 08-09-2011

Research Scientist
Cancer Program (Head: Todd R. Golub, MD)
Broad Institute of Harvard and MIT, Cambridge, MA, USA
from 02-01-2007 to 30-10-2016

Faculty Instructor in Pediatrics (Assistant Professor equivalent)
Harvard Medical School, Boston, MA
Department of Pediatric Oncology
Leukemia Program (Head: Stuart H. Orkin, MD, PhD; David A. Williams, MD.: Scott A. Armstrong, MD, PhD)
from 08-09-2011 to 30-10-2016

HIGHLY SPECIFIC TRAINING

2005	Training in DHPLC technology in the laboratory of Dr. Marco Tartaglia, Istituto Superiore di Sanità, Rome, Italy
2006	Transgenomic course for Wave System, Pavia, Italy
2007	Broad Institute Gene Pattern Workshop
2008	Broad Institute Gene Pattern Workshop
2011	Broad Institute Gene Pattern Workshop
2015	Introduction to RNAseq Analysis (DFCI-Boston Childrens Hospital)
2015	Technical training for <i>in vivo</i> mice work
2017	GCP Compliance Training for HCPs V2.0

MEMBERSHIP

2006-	Member, European Hematology Association (EHA)
-------	---

2009- Member, American Society of Hematology (ASH)
2016- Italian Society of Experimental Hematology (SIES)

HONORS, AWARDS, AND PRIZES

2005 Travel grant. 40th Italian society of Hematology, Bergamo, Italy
2006 "Mauro Felli", Young Researcher Award. CIRIAF University of Perugia, Italy
2007-2008 European Hematology Association-American Society of Hematology (EHA-ASH) International Award
2008 Travel grant. 13th European Hematology Association Congress
Travel grant. American Hematology Association 51st Meeting
2009-2010 Lady Tata Memorial Trust. International Awards for Research in Leukemia.
2010 "Silvia Fiocco" Young Researcher Award for Excellence in Leukemia Research, Accademia Nazionale dei Lincei, Roma
2010-2013 Leukemia and Lymphoma Society "Special Fellow" Award
2011 ASH Abstract Achievement Award, American Society of Hematology
2014 Claudia Adams Barr Award, Dana-Farber Cancer Institute
Young Investigator Award, Fondazione Guido Berlucchi
ASH Abstract Achievement Award, American Society of Hematology
2016 ASH Abstract Achievement Award, American Society of Hematology
Seal of Excellence. EU Framework Programme for Research and Innovation 2014-2020. Project proposal 750679
2017 Gianni Bonadonna Prize for New Drug Development in Oncology, Finalist
Best abstract presented at the Italian Society of Experimental Medicine meeting. Parma
2018 Gilead International Scholar award
Seal of Excellence. EU Framework Programme for Research and Innovation 2014-2020. Project proposal 838166
2019 Giovanni di Guglielmo Award for Excellence in Leukemia Research. Accademia Nazionale dei Lincei.
2019 AIMS Award: Artificial Intelligence Molecular Screen (AIMS) Awards program by Atomwise for academic researchers seeking novel compounds to treat disease
2021 Hollis Browstein scholar

FUNDING INFORMATION (PI)

1999	Grant "Erasmus". European Grant for academic mobility, Université Claude Bernard Lyon II, France	n/a
2007	Grant "L. Fontana e M. Lionello" 2007 FIRC (Fondazione Italiana per la Ricerca sul Cancro)	\$25.000
2007-2008	European Hematology Association-American Society of Hematology (EHA-ASH) International Fellowship Award	\$75.000
2009-2010	American-Italian Cancer Foundation International Post-Doctoral Research Fellowship	\$70.000
2009-2011	Lady Tata Memorial Trust. International Awards for Research in Leukaemia	£50.000
2011-2012	Grant 2011-Progetti di Ricerca. Fondazione Umberto Veronesi, Italy	€100.000
2010-2013	Leukemia and Lymphoma Society "Special Fellow" Award	\$195.000
2011-2016	Italian Minister of Health. Bando Ricerca Finalizzata Giovani Ricercatori	€317.767
2013-2016	International Fellowship. Fondazione Umberto Veronesi, Italy	€71.000
2014-2016	Claudia Adams Barr Program in Cancer Research/ Innovative Basic Science Research	\$380.000
2017-2021	Start-up GRANT. Associazione Italiana Ricerca sul Cancro (AIRC)	€1.000.000
2017	Horizon 2020-Research Infrastructure. Corbel EU program	€100.000
	Cariparma foundation research grant 3576/2017	€40.000

	Grande Ale research grant	€10.000
2018	Gilead International Scholar award	\$130.000
	Cariparma foundation research grant 0180/2018	€100.000
	Grande Ale research grant	€10.000
2019	University of Parma-Feliciani Ferretti grant	€24.000
	POR FESR 2014-2020. SUPER: Supercomputing Unified Platform	€50.000
	Multi-PI grant from the Emilia Romagna health board	
2019	AIMS Award: Artificial Intelligence Molecular Screen (AIMS) Awards program by Atomwise for academic researchers seeking novel compounds to treat disease	€100.000
2019	AIRC-Investigator Grant. Co-PI. A Radio-Immuno-Genomic Approach to Identify Prognostic and Predictive Models for the Response to Immunotherapy in NSCLC. Task: Genomic and computational core.	€1.119.000
2020	Grande Ale research grant	€15.000
2020-2021	Leukemia Research Foundation	\$100.000
2021-	GIMEMA per le Idee (<i>collaborator</i>)	€192.000
2021-	FIN-RER (Regional Cooperative Project)	€400.000
2021-	IFAB Foundation	€136.000
2022-	Minister of Health. "Creazione di un programma di medicina di precisione per la mappatura del genoma umano su scala nazionale" - Piano Sviluppo e Coesione Salute.	€3.693.646,57
2022-2026	PNRR – M4C2 – I1.1 - PRIN 2022 - ERC LS4 -Next Generation EU	€54,146
2023-	AIRC-Investigator Grant. Targeting the Atypical Kinome in T-cell Acute Lymphoblastic Leukemia (IG-2022)	€1.093.721
2023-2025	Call for IDEAs 2023 Fondazione TIM. Profilo Predittivo di Risposta ai Farmaci (P-DRP) nelle Leucemie "Hopeless".	€369.000
2023-2027	GIMEMA AML2326 "Novel approaches to target MECOM/EV1 in Acute Myeloid Leukemia"	€160.000
2024-2025	PNRR- M4C2 – I1.4 Leukemia Drug Response Profile Screening (LDRscreen): a Multiomic Modelto - ERC LS4 -Next Generation EU	€400.000
2024-2026	PNRR-MCNT2-2023-12378065, "Novel approaches for characterization and therapeutic targeting of T-cell acute lymphoblastic leukemia (T-ALL)	€250.000
2025	Human Technopole's National Facilities Research Grant	€100.000
2026-	FIS-2024-05611, Fondo Italiano per la Ricerca, Bando FIS3, LS-I37	€1.864975,76

FUNDING INFORMATION (Mentor)

2018	Matteo Marchesini, Ph.D. EHA-ASH Translational Research Training in Hematology (TRTH-Award)
	Claudia Sorrentino, Ph.D. Fondazione Umberto Veronesi Fellowship
2019	Claudia Sorrentino, Ph.D. Fondazione Umberto Veronesi Fellowship
2020	Anna Montanaro, Ph.D. student Rotary International Foundation
2020	Claudia Sorrentino, Ph.D. Associazione Italiana Ricerca sul Cancro Fellowship
2020-21	Anna Montanaro, Ph.D. student Italian Society of Experimental Hematology International Fellowship
2020-21	Matteo Marchesini Ph.D., Italian Society of Experimental Hematology-Beat Leukemia Foundation Fellowship
2025	Luciano Nicosia Ph.D., AIRC Fellowship
2025	Maria Teresa Giaimo M.D., Fondazione Veronesi Clinical fellowship Program
2025	Sabrina Testa M.D., Fondazione AIRC Physician Scientist Project
2025	Luciano Nicosia, Ph.D. AIRC-International Fellowship

REFEREE ACTIVITY

Agency

2011	Ministero della Salute. Minister of Health. Bando per la Ricerca Finalizzata 2010
2012	Harvard Catalyst Advanced Imaging Pilot Research Grants Program, Harvard Medical School Boston American Society of Hematology, Annual Meeting, Atlanta Georgia, USA FWO, Flanders Foundation, Belgium
2014	Ministero della Salute. Minister of Health. National Grant. Bando per la Ricerca Finalizzata 2010
2016	American Society of Hematology, Annual Meeting, San Diego California, USA Italian Minister of Research-Rita Levi Montalcini Program
2017	FWO, Flanders Foundation, Belgium AIFA. Agenzia Italiana del Farmaco-Italian Medicines Agency Italian Minister of Research- Unicalabria grant
2018	Under40 in Hematology. Scientific committee panel expert Leuka-Leading leukemia research Ministero della Salute. Minister of Health. National Grant. Bando per la Ricerca Finalizzata 2017-8
2019	Ministero della Salute. Minister of Health. National Grant. Bando per la Ricerca Finalizzata 2018-9 Under40 in Hematology. Scientific committee panel expert
2020	Ministero della Salute. Minister of Health. National Grant. Bando per la Ricerca Finalizzata 2019-20
2021	Kikka Foundation, Netherland
2022	American Society of Hematology, Annual Meeting, New Orleans, USA

Journal

2011-	<i>Among others:</i> Leukemia, Cell Death and Disease, Blood, Clinical Cancer Research, Annals of Hematology, Nature Communication, Scientific reports
-------	--

Scientific Board

2017-	Grande Ale Foundation
2019-	SIES. Società Italiana di Ematologia Sperimentale. Emilia Romagna Chapter
2023-	IFAB-Foundation
2024	EHA Grants & Fellowship

MEETINGS

Works limited to oral presentation

International

2008	American Hematology Association 50 th Meeting, San Francisco Leukemia/Lymphoma Society SCOR Meeting, Boston 13 th European Hematology Association Congress, Copenhagen
2009	American Hematology Association 51 st Meeting, New Orleans Leukemia/Lymphoma Society SCOR Meeting, Boston
2010	Broad Institute Cancer Program Meeting, Cambridge Leukemia/Lymphoma Society SCOR Meeting, Boston
2011	American Hematology Association 53 rd Meeting, San Diego Leukemia/Lymphoma Society SCOR Meeting, Boston
2013	Broad Institute Cancer Program Meeting, Cambridge Leukemia/Lymphoma Society SCOR Meeting, Boston

2014	American Hematology Association 55rd Meeting, San Francisco
2015	Leukemia/Lymphoma Society SCOR Meeting, Boston
2016	Leukemia/Lymphoma Society SCOR Meeting, Boston
2017	T-ALL International Workshop. Leuven Belgium
2019	International NOTCH meeting. Cyprus
2019	American Hematology Association 61st Meeting, Orlando
2020	24 th Congress of the European Hematology Association
2021	25 th Congress of the European Hematology Association
2022	American Hematology Association 63 rd Meeting, New Orleans
	ALL, Assembly 2022 Madrid, Spain
2023	American Hematology Society 65 th Meeting, San Diego
2024	3 rd Translational research Conference on CLL, Vienna
	European Hematology Association Hybrid Congress, Madrid
	4 th European School of Hematology, Stockholm
2025	4rd Translational Research Conference Acute Lymphoblastic Leukemia, Malahide-Dublin
	European Hematology Association Hybrid Congress, Milano
2026	5 th European School of Hematology, Mandelieu-La Napoule
	31 st Congress of the European Hematology Association, Stockholm

National

2004	Italian Society of Experimental Medicine meeting Pavia
2005	40 th SIE meeting Italian society of Hematology, Bergamo
2009	1 st Translational Research in Hematology Meeting, Città Della Pieve
2011	Seminars in Molecular Medicine, Genomics and Cancer: New Frontiers, Perugia
2017	AIRC National Cancer Meeting. Napoli
2017	Italian Society of Experimental Medicine meeting Parma
	Keynote speech. Nerviano Medical Sciences. Oncology Seminars.
2018	Seminar in clinical medicine, Bologna
	University of Trento: "Where Science Meets Technologies"
	University of Padova: Seminars in Hematology
2019	Keynote speech. Italian Society of Experimental Hematology, Milano
	Italian Society of Hematology Meeting. Piacenza
2021	Keynote speech. Italian Society of Experimental Hematology, Milano
	" New Biological Insights and Novel Drugs in Acute Leukemia", Venezia
	Keynote speech. Italian Society for Leukemia Research
	" Can We Predict the Chemosensitivity of Leukemia", AIL-Leukemia, Rome
2022	Keynote speech." Intersecting Genomic Medicine and System Pharmacology for Profiling Therapeutic Sensitivity in Leukemia", Mestre, Italy
	17 th SIES Meeting Italian Society of Experimental Hematology, Roma
2024	18 th SIES Meeting Italian Society of Experimental Hematology, Firenze
2025	52 th SIE Meeting Italian Society of Hematology, Milano
2026	XIX SIES Meeting Italian Society of Experimental Hematology, Firenze

SCIENTIFIC CONTRIBUTION

1. Over the course of my medical training there have been major advances in our understanding of the molecular basis of disease. My mentors at the University of Perugia (Prof. B. Falini and Prof. C. Mecucci) were contributing to those advances making the ground-breaking identification of *NPM1* mutations in acute myelogenous leukemia (AML). Although at that time *NPM1* was easy to identify with an immunohistochemistry assay this approach was not manageable for the identification of mutations in a large cohort of sample. As such, I developed what it was considered at time a high-throughput assay for the identification of *NPM1* mutations leukemia based on Denaturing High

Performance Liquid Chromatography. DHPLC is a method based on reverse phase chromatography for the detection of base substitutions, small deletions or insertions at the DNA. This approach led to a first author publication and several as co-authors. Additionally, I applied this approach to identification of mutation associated with genetic disease.

- a) **Roti G**, Rosati R, Bonasso R, Gorello P, Diverio D, Martelli MF, Falini B, Mecucci C. DHPLC: a valid approach for identifying NPM1 mutations in acute myeloid leukaemia. *Journal of Molecular Diagnostics*, 2006, 8: 254-259
 - b) Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E., Pallotta MT, Diverio D, Nicoletta I, Pacini R, Tabarrini A, Verducci Galletti B, Mannucci R, **Roti G**, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo Coco F, Saglio G, Pelicci PG, Martelli MF, Mecucci C. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.. *Blood* 2006, 108(6):1999-2005
 - c) **Roti G**, La Starza R, Ballanti S, Crescenzi B, Romoli S, Foà R, Tartaglia M, Aversa F, Martelli MF, Mecucci C. Acute lymphoblastic leukemia in Noonan syndrome. *British Journal of Hematology* 2006, 133:448-450
2. In 2007 I joined the laboratory of Dr. Kimberly Stegmaier at the Dana-Farber Cancer Institute and The Broad Institute of Harvard and MIT. In Dr. Stegmaier laboratory I initially extended the Gene Expression-based High-throughput Screening application (GE-HTS) to the challenge of targeting transcription factor abnormalities in cancer. I initially applied this platform to the identification of transcription factor modulators of known oncogenes in acute myeloid leukemia (AML1/ETO). This work led the identification of corticosteroids and dihydrofolate reductase (DHFR) inhibitors as new modulators of AML-1/ETO the most common translocation reported in AML. Furthermore, I collaborated to a project that led to the identification of GSK-3 α as a new target in AML. I served as the primary investigator or co-investigator in all of these studies.
- a) Corsello SM[#], **Roti G**[#], Ross KN, Chow KT, Galinsky I, Stone RM, DeAngelo DJ, Kung AL, Golub TR, Stegmaier K. Identification of AML1-ETO modulators by chemical genomics. *Blood*. 2009 Jun 11;113(24):6193-205. PMID: PMC2699238. [#] These authors contributed equally to this work.
 - b) Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, Kakoza RM, Chow KT, Ross L, Alexe G, Tolliday N, Inguilizian H, Galinsky I, Stone RM, DeAngelo DJ, **Roti G**, Aster JC, Hahn WC, Kung AL, Stegmaier K. The intersection of genetic and chemical genomic screens identifies GSK-3 α as a target in human acute myeloid leukemia. *J Clin Invest*. 2012 Mar 1;122(3):935-47. PMID: PMC3287215.
3. Although the identification a limitation of cell-based assays including GE-HTS is that identifying the biologically relevant target of the small molecule can be a daunting task. One way to overcome this challenge is to design multiple, integrated cell-based screens and then to focus on common emerging hits. As such I performed a small-molecule library screen to identify modulators of mutated NOTCH1 in T-ALL and integrating these results with a cell-based screen for cDNA enhancers of a NOTCH1 allele bearing a leukemia-associated mutation. SERCA emerged at the intersection of these complementary approaches. I discovered that SERCA inhibition impairs the maturation of mutated NOTCH1 receptors and induces a G0/G1 arrest in NOTCH1-mutated human T-ALL cells. A small-molecule SERCA inhibitor, thapsigargin, had on-target activity in mouse models of human T-ALL and also interfered with Notch signaling in *Drosophila*. Remarkably, thapsigargin preferentially inhibited mutated NOTCH1 receptors. This selectivity provides a therapeutic window not observed with other Notch pathway inhibitors, such as γ -secretase inhibitors or antibody-based approaches that are equipotent inhibitors of mutated and wild-type receptors. However, the immediate consequence of thapsigargin binding to SERCA is a raise in cytosolic Ca²⁺ concentration and a depletion of Ca²⁺ stored in the endoplasmic reticulum. Thus, the direct delivery of thapsigargin to humans might be expected to incur cardiac toxicity secondary to calcium ion shifts. An emerging strategy to deliver highly toxic small molecule such as thapsigargin is to develop a prodrug. I demonstrated that T-ALL

cells express high copies of folic acid receptor thus enabling the development of folate receptor-mediated endocytosis delivery strategies for anticancer therapeutics. In collaboration with Dr. James Bradner and Jun Qi at the Dana-Farber Cancer Institute we developed folate thapsigargin the first in class anti NOTCH1 therapeutics with dual selectivity leukemia vs. normal cells and mutated vs. wild-type NOTCH1 receptors. My work pointed to the role of Ca^{2+} signaling in Notch regulation and also led the identification of bepridil (a Ca^{2+} blocker) as potential Notch modulator. This FDA approved small molecules is now being tested in preclinical studies in chronic lymphocytic leukemia. In my laboratory at the University of Parma we are expanding this idea and developing new SERCA inhibitors. From a 191000 small molecules P-type ATPase screening we identified CAD204520 a modulator with the unique property to binds SERCA in a pocket different from the thapsigargin one, avoiding Ca^{2+} related cardiac toxicity. Furthermore, this molecule targets the most frequently *NOTCH1* mutation in chronic lymphocytic leukemia (PEST deletion).

- a) Pagliaro L, Chen SJ, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, Zhang M, Chen Z, Boissel N, Winter SS, **Roti G**. Acute lymphoblastic leukaemia. *Nat Rev Dis Primers*. 2024 Jun 13
- b) Pagliaro L, Cerretani E, Vento F, Montanaro A, Moron Dalla Tor L, Simoncini E, Giaimo M, Gherli A, Zamponi R, Tartaglione I, Lorusso B, Scita M, Russo F, Sammarelli G, Todaro G, Silini EM, Rigolin GM, Quaini F, Cuneo A, **Roti G**. CAD204520 Targets *NOTCH1* PEST Domain Mutations in Lymphoproliferative Disorders. *Int J Mol Sci*. 2024
- c) Marchesini M., Gherli A., Montanaro A., Patrizi L., Sorrentino C., Pagliaro L., Rompietti C., Kitara S., Heit S., Olesen C. E, Møller J. V, Savi M., Bocchi L., Vilella L., Rizzi F., Baglione M., Rastelli G., Loiacono C., La Starza R., Mecucci C., Stegmaier K., Aversa F., Stilli D., Lund Winther A.M., Sportoletti P., Bublitz M., Dalby-Brown W., **Roti G**. Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell Chem Biol*. 2020 Apr 15;S2451-9456(20)30116-1
- d) **Roti G**, Qi J, Kitara S, Varca CA, Sanchez-Martin M, Kung AL, Ferrando AF, Bradner JE, Stegmaier K. Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. *J Exp Med*. 2018 Jan 2;215(1):197-216
- e) **Roti G**, Carlton A, Ross KN, Markstein M, Pajcini K, Perrimon N, Pear WS, Kung AL, Blacklow SC, Aster JC, Stegmaier K. Complementary genomic screens identify SERCA as a therapeutic target in *NOTCH1* mutated cancer. *Cancer Cell*. 2013 Mar 18;23(3):390-405. PMCID: PMC3709972.

As featured in Cancer Cell. 2013 Mar 18;23(3):267-9. Ilagan MX, Kopan R. Selective blockade of transport via SERCA inhibition: the answer for oncogenic forms of Notch?

As featured in Nat Med. 2013 May;19(5):546. Boettner B. Cancer therapy: A Notch further with SERCA.

As featured in Cancer Res April 1, 2013 73; 2023

- f) **Roti G**, Ross KN, Blacklow SC, Aster JC, Stegmaier K. Expression-based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL. Presented at the American Hematology Association 51th Meeting, New Orleans 4-8 December 2009.
 - g) Baldoni s, Del Papa B, Aureli P, Dorillo E, De Falco F, Varasano E, Cecchini D, Zei T, Di Tommaso T, Rosati E, Gabriela A, **Roti G**, Stegmaier K, Di Ianni M, Falzetti F, Sportoletti P. Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. *International journal of cancer*. 2018 vol. 143, p. 958-970
 - h) **Roti G** and Stegmaier K. New Approaches to Target T-ALL. *Front Oncol*. 2014 Jul 8;4:170. PMCID: PMC4085879.
4. One of the approaches I focused is the identification of new potential cancer targets at the intersection of complementary “omic” approaches for pediatric cancers. I contributed to developing platforms for identifying epigenetic dependencies or mechanisms of resistance in leukemia, brain tumors, and neuroblastoma.

As an independent researcher at the University of Parma, I have further expanded this concept, focusing on two main approaches. The first involves screening strategies aimed at identifying modulators and epigenetic residues in T-cell acute lymphoblastic leukemia (T-ALL). In this context, we have identified a target known as EHMT2/G9a which is pharmacologically targetable. Preliminary studies have suggested a potential dependency on this target in the disease.

The second project is a major effort focused on the most aggressive subtype of acute myeloid leukemia (AML) characterized by 3q26 rearrangement and *MECOM* overexpression. This is an extremely aggressive malignancy with a life expectancy of less than 24 months. Through a high-throughput screening of over 10,000 molecules, we identified a class of drugs that can potentially modulate this protein in vitro and in preclinical models. We translated these findings into a clinical experience, demonstrating an anti-leukemic effect in treated patients. Furthermore, by employing innovative mass spectrometry technologies, we uncovered the mechanism underlying the activity of this drug class in this leukemia, leading to the identification of a novel target. We are now working on the development of a new inhibitor for this target.

- a) Marchesini M, Gherli A, Simoncini E, Tor LMD, Montanaro A, Thongon N, Vento F, Liveni C, Cerretani E, D'Antuono A, Pagliaro L, Zamponi R, Spadazzi C, Follini E, Cambò B, Giaino M, Falco A, Sammarelli G, Todaro G, Bonomini S, Adami V, Piazza S, Corbo C, Lorusso B, Mezzasoma F, Lagrasta CAM, Martelli MP, La Starza R, Cuneo A, Aversa F, Mecucci C, Quaini F, Colla S, **Roti G**. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML. *Nat Commun*. 2024 Jun 4
 - b) Montanaro A, Kitara S, Marchesini M, Gherli A, Su A, Fioretzaki R, Ross L, Alexe G, Sabrina Bonomini S, Masselli E, Xiong Y, Jin J, Falco A, Knoechel B, Aversa F, Quaini F, Stegmaier K, **Roti G**. Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell Acute Lymphoblastic Leukemia. *Cell Death and Disease* 2022 (13):551.
 - c) Bandopadhyay P, Piccioni F, O'Rourke R, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nat Commun*. 2019;10(1):2400. Published 2019 Jun 3. doi:10.1038/s41467-019-10307-9
 - d) Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, **Roti G**, Kung AL, Bradner JE, Tolliday N, Stegmaier K. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. *Chem Biol*. 2013;20(5):713-725.
 - e) **Roti G**, Stegmaier K. Genetic and proteomic approaches to identify cancer drug targets. *Br J Cancer*. 2012;106(2):254-261.
 - f) Iniguez AB, Alexe G, Wang EJ, **Roti G** et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer Cell*. 2018;34(6):922-938.e7.
5. More recently, I am developing a platform for personalized cancer therapeutics by testing in clinical leukemia samples upfront sensitivity or resistance to a collection of ~ 80 approved small molecules. This work led to the identification of a new therapeutic approach in T-ALL (m) but also it is the base of a national clinical trial to inform therapies based on the integration of chemogenomic approaches.
- a. La Starza R, Cambò C, Pierini A, Bornhauser B, Montanaro A, Bourquin JP, Mecucci C, **Roti G**. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. *JCO Precision Oncology*, 2019 Sep 20;3:PO.19.00172.
 - b. Omics approaches For Leukemia Target Identification and Matched Therapeutic Intervention FINRER 2020
 - c. NCT04582487 GIMEMA National Trial ALL-2720. Advancing chemical and genomic strategies for relapsed/refractory T-ALL and ETP-ALL

CLINICAL CONTRIBUTION

1999-2000	Internship in Internal Medicine, (Centre Hospitalier. Lyon Sud Hcl-Pierre Benite, Université Claude Bernard Lyon II, France). Inpatient care of general medicine patients, including Diabetes & Endocrinology; Hematology; Rheumatology; Cardiology (Hospital Cardiologique Louis Pradel Lyon, Université Claude Bernard Lyon II, France). Internship in Orthopedic Surgery (Centre Hospitalier Lyon Sud Hcl-Pierre Benite, Université Claude Bernard Lyon II France).
2000-2002	Internship in Internal Medicine and Hematology, (Ospedale Maggiore di Parma, University of Parma, Italy). Inpatient care of general medicine patients, including: Diabetes & Endocrinology; Hematology; Respiratory Medicine; Gastroenterology; Cardiology; Nephrology.
2002	Out-of-hours General Practitioner's Service for the Emilia Romagna Health Board.
2002-2006	Fellow in Hematology and Bone Marrow Transplantation (BMT) (Ospedale S.Maria della Misericordia, University of Perugia, Italy). Hemato-oncologic inpatient management, including acute management of complications, high dose chemotherapy, PBSC mobilization, autologous stem cell transplant, allogeneic stem cell transplant from matched and unmatched sibling donors. Management of general Hematology patients, including: hemoglobinopathies, acquired and inherited bleeding disorders. Management of hematological malignancy outpatients, including myeloproliferative disorders, myelodysplastic syndromes, plasma cell disorders, Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia in the Day Hospital settings. Out-patient management of new patients and their diagnostic workup for general Hematology and hemato-oncology.
2004-2006	Out-of-hours General Practitioner's Service for the Umbria Health Board.
2017-2024	Attending physician at Hematology and BMT unit, University teaching hospital, Parma, Italy
2023-	<i>Clinical pathology. Scientific Head Next Generation Sequencing platform for the Emilia Romagna Northern Region. AOU-PR</i>
2019-2021	Attending physician at Internal Medicine, AO Mantova, Italy for COVID pandemic support
2024-	<i>Head Hematology and Bone Marrow Transplant Unit. AOU-PR</i>

ACADEMIC CLINICAL TRIAL DEVELOPMENT

2020	"Advancing chemical and genomic strategies for relapsed/refractory T-ALL and ETP-ALL"	GIMEMA ALL2720	National PI Local PI	NCT04582487
2021	Novel Approaches to Target EVI1 in Acute Myeloid Leukemia	GIMEMA	National PI	t.b.a
2022	Integrative "omics" approaches for leukemia target identification and matched therapeutic intervention.	Emilia-Romagna Health Board	National PI	t.b.a

TEACHING AND MENTORING ACTIVITY

2011-	My experience as a research supervisor started at the Harvard Medical School as an Instructor in Pediatrics in the Department of Pediatric Oncology of DFCI. I mentored several Boston Medical and Harvard Medical School students (HMS). I supervised Ph.D. students currently in their first post-doctoral research experience in prestigious academic cancer centers. Angela Su and Samuel Kitara were the two talented laboratory technicians who worked more closely with me after completing college from 2012 to late 2016. Angela is a senior laboratory manager at St. Louis Hospital in Paris and Samuel completed an MBA-MD competitive program at Yale University. I supported Mr. Kitara by applying to the
-------	--

prestigious Agha Khan International Award that helps students from low-income countries to achieve higher education. Mr. Kitara recently signed a contract at Gilead.

In my most recent experience at the University of Parma, I am responsible for teaching activity in a protected capacity, and every year I supervise a minimum of two M.D. students. I am currently mentoring three Ph.D. students and two post-doctoral fellows. In the last three years three of my post-docs transitioned to an independent academic position.

- 2017- Medical School. Hematology, University of Parma
- 2017- Nursing School. Internal Medicine, University of Parma
- 2017- Ph.D. Program. Department of Medicine and Surgery, University of Parma, Italy
- 2017- Molecular-Therapy. Bachelor of Science program. University of Parma, Italy
- 2020- Master's in clinical Trial. University of Parma, Italy

TEACHING COURSES

CFU *Courses (CDL) at University of Parma*

- 1 "Prevention techniques in the environment and in the workplace (qualifying for the health profession of prevention technician in the environment and in the workplace) - Blood Diseases Module"
- 3 "Medical, veterinary and pharmaceutical biotechnologies - Molecular Therapies Module"
- 1 "Nursing (qualifying for the health profession of nurse) - Clinical Medical teaching - Specialized Medicine"
- 3 Medicine and Surgery – Hematology Module
- 1 "Fellowship program of Hematology"
- 1 "Fellowship program in Infectious and Tropical Diseases"
- 1 "Fellowship program of Pathology"

Seminars Organization - University of Parma

- 2017- Hematology & Oncology seminar series

PUBLICATIONS

Complete List of Published Work in My Bibliography

<https://pubmed.ncbi.nlm.nih.gov/?term=Giovanni%20Roti&page=3>

ORCID ID:0000-0002-8664-950X

RESEARCH ID:A-4234-2015

Scopus Author Id:12808329800

Laboratory link: <https://labthec.com/about-us/people/>

SCOPUS

H index: 28

Total citation: 2549

Mean Citation: 33,86

Total Impact Factor: 696,092 – 2021 Journal Impact Factor

Mean Impact Factor: 12,2121

n. and total IF of publications where the candidate is first author equivalent (for the disciplines where the position in the list of authors corresponds to the role in the work presented): 9 – 116,721

N. and total IF of the publications where the candidate is the last or corresponding author (for the disciplines where the position in the list of authors corresponds to the role in the work presented): 9 – 59,333

Montanaro A., Monica G., Zamponi R., D'Antuono A., Andreani A., Andrei P., Su A., Ciringione A., Sammarelli G., Todaro G., Rosati R., La Starza R., Mecucci C., Elia L., Gherli A., Vento F., Simoncini E., Lorusso B., Lagasta C.A.M., Giaimo M., Pagliaro L., Marchesini M., Jimenez C.R., Quaini F., Stegmaier K., **Roti G.** Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell Acute Lymphoblastic Leukemia. *Blood* 2026 May 19: blood.2025029901. doi: 10.1182/blood.2025029901. Online ahead of print.

Di Giacomo D., Pölönen P., Bardelli V., Kimura S., Pierini V., Pagliaro L., Arniani S., Chang Y., Gao Q., Montefiori L.E., Wu Y., Park C.S., Wright W.C., Vento F., Wei H., Matteucci C., Lei S., Rosikiewicz W., Nardelli C., Lema Fernandez A.G., Østergaard A., Backhaus E.A., Baviskar P., Cerrano M., Leoncin M., Manabe A., Hirabayashi S., Takita J., Hasegawa D., Miyamoto S., Macchiarulo A., Xu J., Teachey D.T., **Roti G.**, Iacobucci I., La Starza R., Mecucci C., Mullighan C.G. Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia. *Blood* 2026 Mar 6: blood.2025031402. doi: 10.1182/blood.2025031402. Online ahead of print.

Merli M., Genuardi E., Zibellini S., Rattotti S., Spina M., **Roti G.**, Motta M., Piazza F., Boccomini C., Ferreri AJM., Perbellini O., Brociner M., Doderò A., Vallisa D., Pulsoni A., Santoro A., Del Giudice I., Zuccaro V., Chimienti E., Russo S., Varrasco C., Rizzo E., Bosi A., Cappello E., Favrin G., Marcheselli L., Visco C., Luminari S., Passamonti F., Ferrero S., Arcaini L. Direct-Acting antiviral agents in hepatitis C-Associated Indolent Lymphomas. *N Engl J Med.* 2026, Jan 1; 394(1): 93-96. Doi: 10.1056/NEJmc2513023. **IF 78,5**

Moschella B, Busciglio S, Ambrosini E, Cesarini S, Caramanna L, Zanelli S, Cannizzaro IR, Luberto A, Taiani A, Treccani M, De Sensi E, Caggiati P, Azzoni C, Bottarelli L, Lorusso B, Lagrasta CAM, Montanaro A, Pagliaro L, Zamponi R, Gherli A, Martorana D, Dominici MM, De Felici Del Giudice MB, Mozzoni P, Silini EM, Neri I, Feliciani C, **Roti G**, Uliana V, Barili V, Percesepe A. Genetics of Darier's Disease: new Insights into Pathogenic Mechanisms. *Genes (Basel.)*, 2025 May 23;16(6):619. doi: 10.3390/genes16060619. **IF 2.8**

Vanhooren J, Deneweth L, Pagliaro L, Ren Z, Giaimo M, Zamponi R, **Roti G**, Depreter B, Hofmans M, De Moerloose B, Lammens T. Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. *Int. J. Mol. Sci.*, 2025 Mar 26;26(7):3011. doi: 10.3390/ijms26073011. **IF 4.9**

20

Mastrodicasa E, Pagliaro L, Pierini V, Bardelli V, Giaimo M, Zamponi R, Montanaro A, Tragni K, Arcaleni R, Massei MS, Capolsini I, Perruccio K, Varotto E, Buldini B, Gherli A, Romoli S, Matteucci C, Crocioni M, Arcioni F, Gurdo G, Cerri C, Caniglia M, **Roti G**, la Starza R. Ex vivo drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with PICALM::MLLT10. *Haematologica*. Oct. 2025, Vol. 110, pp.2535-2542. **IF 7.9**

Mazzaschi G, Marrocchio C, Moron Dalla Tor L, Leo L, Balbi M, Milanese G, Adebajo GAR, Lorusso B, Monica G, Pluchino M, Minari R, D'Agnelli S, Cardinale E, Perrone F, Bordi P, Leonetti A, Ledda RE, Silvia M, Buti S, **Roti G**, Bettati S, Quaini F, Tiseo M, Sverzellati N. Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns of acquired resistance to immunotherapy in patients with NSCLC. *Clin. Cancer Res.*, Apr. 15 2025, Vol. 31 (8), pp. 1533-1545. doi: 10.1158/1078-0432.CCR-24-1926 **IF 10.2**

Mosna F, Borlenghi E, Litzow M, Byrd JC, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan EA, Gurrieri C, Yeung CCS, Deeg HJ, Capelli D, Candoni A, Gotlib JR, Lunghi M, Pullarkat S, Lanza F, Galimberti S, Forghieri F, Venditti A, Festuccia M, Audisio E, Marvalle D, Rigolin GM, **Roti G**, DiBona E, Visani G, Albano F, Eisfeld AK, Valent P, Huls G, Borthakur G, Krampera M, Martinelli G, Kroger N, Sperotto A, Gottardi M. Long-term survival can be achieved in a significant fraction of holder patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy. *Haematologica*. 2025 Mar 1; 110(3): 608-620. Doi: 10.3324/haematol.2024.285448 **IF 8.2**

Balbi M, Mazzaschi G, Leo L, Moron Dalla Tor L, Milanese G, Marrocchio C, Silva M, Mura R, Favia P, Bocchialini G, Trentini F, Minari R, Ampollini L, Quaini F, **Roti G**, Tiseo M, Sverzellati N. Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. *J Thorac Imaging*. 2025 Jan 1;40(1):e0801.doi: 10.1097/RTI.0000000000000801. **IF 2.0**

Guidetti L, Castelli R, Zappia A, Ferrari FR, Giorgio C, Barocelli E, Pagliaro L, Vento F, **Roti G**, Scalvini L, Vacondio F, Rivara S, Mor M, Lodola A, Tognolini M. Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line. *Eur J Med Chem*. 2024 Oct 5, Vol. 276, 116681. **IF 6.0**

Lorusso B, Nogara A, Fioretzaki R, Corradini E, Bove R, **Roti G**, Gherli A, Montanaro A, Monica G, Cavazzini F, Bonomini S, Graiani G, Silini EM, Gnetti L, Pilato FP, Cerasoli G, Quaini F, Lagrasta CAM. CD26 is differentially expressed throughout the life cycle of infantile hemangiomas and characterizes the proliferative phase. *Int J Mol Sci*. 2024 Sep 10; 25(18): 9760. **IF 4.9**

Guerra L, Chauvie S, Fallanca F, Bergesio F, Marcheselli L, Durmo R, Peano S, Franceschetto A, Monaco L, Barbieri E, Ladetto M, Musuraca G, Tosi P, Bianchi B, Bolis SAM, Pavone V, Chiarenza A, Arcari A, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, **Roti G**, Galimberti S, Gini G, Falcinelli F, Vitolo U, Usai SV, Stefani PM, Ibatici A, Liberati AM, Pennese E, Perrone T, Versari A, Luminari S. Fondazione Italiana Linfomi (FIL). End of induction [¹⁸F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. *Eur J Nucl Med Mol Imaging*. 2024 Sep;51 **IF 8.6**

Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, **Roti G**, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. *Haematologica*. 2024 Jul 1; 109(7):2297-2302. **IF 8.2**

Pagliaro L, Chen SJ, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, Zhang M, Chen Z, Boissel N, Winter SS, **Roti G**. Acute lymphoblastic leukaemia. *Nat Rev Dis Primers*. 2024 Jun 13;10(1):41. Doi: 10.1038/s41572-024-00525-x. **IF 76.9**

Marchesini M, Gherli A, Simoncini E, Tor LMD, Montanaro A, Thongon N, Vento F, Liverani C, Cerretani E, D'Antuono A, Pagliaro L, Zamponi R, Spadazzi C, Follini E, Cambò B, Giaimo M, Falco A, Sammarelli G, Todaro G, Bonomini S, Adami V, Piazza S, Corbo C, Lorusso B, Mezzasoma F, Lagrasta CAM, Martelli MP, La Starza R, Cuneo A, Aversa F, Mecucci C, Quaini F, Colla S, **Roti G**. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML. *Nat Commun*. 2024 Jun 4;15(1):4739. Doi: 10.1038/s41476-024-48953-3. **IF 14.7**

Almeida A, T'Sas S, Pagliaro L, Fijalkowski I, Sleeckx W, Van Steenberge H, Zamponi R, Lintermans B, Van Loocke W, Palhais B, Reekmans A, Bardelli V, Demoen L, Reunes L, Deforce D, Van Nieuwerburgh F, Kentsis A, Ntziachristos P, Van Roy N, De Moerloose B, Mecucci C, La Starza R, **Roti G**, Goossens S, Van Vlierberghe P, Pieters T. *Myb* overexpression synergizes with the loss of *Pten* and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia. *Hemasphere*. 2024 Mar 10;8(3):e51. Doi: 10.1002/hem3.51. eCollection 2024 Mar, **IF 7.6**

Pagliaro L, Cerretani E, Vento F, Montanaro A, Moron Dalla Tor L, Simoncini E, Giaimo M, Gherli A, Zamponi R, Tartaglione I, Lorusso B, Scita M, Russo F, Sammarelli G, Todaro G, Silini EM, Rigolin GM, Quaini F, Cuneo A, **Roti G**. CAD204520 Targets *NOTCH1* PEST Domain Mutations in Lymphoproliferative Disorders. *Int J Mol Sci*. 2024 Jan 7;25(2):766. doi: 10.3390/ijms25020766 **IF 4.9**

Fischer J, Erkner E, Fitzel R, Radszuweit P, Keppeler H, Korkmaz F, **Roti G**, Lengerke C, Schneidawind D, Schneidawind C. Uncovering NOTCH1 as a Promising Target in the Treatment of *MLL*-Rearranged Leukemia. *Int J Mol Sci*. 2023 Sep 23 **IF 4.9**

Leoncin, M., La Starza, R., **Roti, G.**, Pagliaro, L., Bassan, R., Mecucci, C. Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine. *Current opinion in oncology* 2022 34 (6), pp. 738-747. **IF 3,645**

Lorusso, B., Cerasoli, G., Falco, A., Frati, C., Graiani, G., Madeddu, D., Nogara, A., Corradini, E., **Roti, G.**, Cerretani, E., Gherli, A., Caputi, M., Gnetti, L., Pilato, F.P., Quaini, F., Lagrasta, C. B-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. *Vascular Pharmacology* 2022, 146, art. no. 107110. **IF 5,773**

Messina, M., Piciocchi, A., Ottone, T., Paolini, S., Papayannidis, C., Lessi, F., Fracchiolla, N.S., Forghieri, F., Candoni, A., Mengarelli, A., Martelli, M.P., Venditti, A., Carella, A.M., Albano, F., Mancini, V., Massimo, B., Arena, V., Sargentini, V., Sciumè, M., Pastore, D., Todisco, E., **Roti, G.**, Siragusa, S., Ladetto, M., Pravato, S., De Bellis, E., Simonetti, G., Marconi, G., Cerchione, C., Fazi, P., Vignetti, M., Amadori, S., Martinelli, G., Voso, M.T. Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. *Cancers* 2022, 14 (12), art. no. 3012. **IF 6,102**

Montanaro A, Kitara S, Marchesini M, Gherli A, Su A, Fioretzaki R, Ross L, Alexe G, Sabrina Bonomini S, Masselli E, Xiong Y, Jin J, Falco A, Knoechel B, Aversa F, Quaini F, Stegmaier K, **Roti G**. Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell Acute Lymphoblastic Leukemia. *Cell Death and Disease* 2022 (13):551. **IF 8.469**

Pikman Y, Ocasio-Martinez N, Alexe G, Dimitrov B, Kitara S, Diehl FF, Robichaud AL, Conway AS, Ross L, Su A, Ling F, Qi J, **Roti G**, Lewis CA, Puissant A, Vander Heiden MG, Stegmaier K. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. *Leukemia*. 2022 Feb;36(2):348-360. Doi: 10.1038/s41375-021-01361-8. **IF 12.883**

Trentini F, Mazzaschi G, Milanese G, Pavone C, Madeddu D, Gnetti L, Frati C, Lorusso B, Lagrasta CAM, Minari R, Ampollini L, Ledda RE, Silva M, Sverzellati N, Quaini F, **Roti G**, Tiseo M. Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients. *Tumori*. 2022 Feb;108(1):86-92. Doi: 10.1177/03008916211000808. **IF 2.149**

Iesato, A., Li, S., **Roti, G.**, Hacker, M.R., Fischer, A.H., Nucera, C. Lenvatinib Targets PDGFR- β Pericytes and Inhibits Synergy with Thyroid Carcinoma Cells: Novel Translational Insights. *Journal of Clinical Endocrinology and Metabolism* 2021, 106 (12), pp. 3569-3590 **IF 5,958**

Pagliaro L, Marchesini M, **Roti G**. Targeting Oncogenic NOTCH Signaling with SERCA Inhibitors. *Journal of Hematology and Oncology*. 2021 Jun 6; (14):17. **IF 14.571**

Di Giacomo, D., La Starza, R., Gorello, P., Pellanera, F., Kalender Atak, Z., De Keersmaecker, K., Pierini, V., Harrison, C.J., Arniani, S., Moretti, M., Testoni, N., De Santis, G., **Roti, G.**, Matteucci, C., Bassan, R., Vandenberghe, P., Aerts, S., Cools, J., Bornhauser, B., Bourquin, J.-P., Piazza, R., Mecucci, C. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. *Blood* 2021, 138 (9), pp. 773-784. **IF 22,113**

Bardelli V, Arniani S, Pierini V, Pierini T, Di Giacomo D, Gorello P, Moretti M, Pellanera F, Elia L, Vitale A, Storlazzi CT, Tolomeo D, Mastrodicasa E, Caniglia M, Chiaretti S, Ruggeri L, **Roti G**, Schwab C, Harrison CJ, Almeida A, Pieters T, Van Vlierberghe P, Mecucci C, La Starza R. MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia. *Genes Chromosomes Cancer*. 2021 Jul;60(7):482-488. **IF 4.263**

Masselli E, Carubbi C, Pozzi G, Percesepe A, Campanelli R, Villani L, Gobbi G, Bonomini S, **Roti G**, Rosti V, Massa M, Barosi G, Vitale M. Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. *Cancers* 2021 May 22;13(11):2552 **IF 6.102**

Gocho Y, Liu J, Hu J, Yang W, Dharia N, Zhang J, Shi H, Du G, John A, Lin T, Hunt J, Huang X , Rowland R, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K , Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, **Roti G**, Litzow M, Zhang J , Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S , Pui C, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans W, Yu J and Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. *Nature Cancer*; March 2021;2(3): 284–299 **IF 24.693**

Nofrini V, Matteucci C, Pellanera F, Gorello P, Di Giacomo D, Lema Fernandez AG, Nardelli C, Iannotti T, Brandimarte L, Arniani S, Moretti M, Gili A, **Roti G**, Di Battista V, Colla S, Mecucci C. Activating somatic and germline TERT promoter variants in myeloid malignancies. *Leukemia*. 2021 Jan; 35(1):274-278 **IF 12.883**

Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debre I, Alexe G, Benoist JF, Pruvost A, Pikman Y, Qi J, Schlageter MH, Micol JB, **Roti G**, Cluzeau T, Dombret H, Preudhomme C, Fenouille N, Benajiba L, Golan HM, Stegmaier K, Lobry C, Wood KC, Itzykson R, Puissant A. The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies. *Cancer Discov*. 2020 Dec;10(12):1894-1911. Doi: 10.1158/2159-8290.CD-19-0970. **IF 39.397**

Pagliaro L, Sorrentino C, **Roti G**. Targeting Notch Trafficking and Processing in Cancers. *Cells*. 2020 Sep 29;9(10): E2212. **IF 6.70**

Pierini T, Nardelli C, Lema Fernandez AG, Pierini V, Pellanera F, Nofrini V, Gorello P, Moretti M, Arniani S, **Roti G**, Giovenali P, Lupattelli M, Metro G, Molica C, Castrioto C, Corinaldesi R, Laurenti ME, Ascani S, Mecucci C, La Starza R. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma. *Acta Neuropathol Commun*. 2020 Aug 25;8(1):145. **IF 6.430**

Mazzaschi G, Milanese G, Pagano P, Madeddu D, Gnetti L, Trentini F, Falco A, Frati C, Lorusso B, Lagrasta C, Minari R, Ampollini L, Silva M, Sverzellati N, Quaini F, **Roti G**[#], Tiseo M[#]. Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer. *Data Brief*. 2020 Jun 2;31:105781. # These authors contributed equally to this work **IF 1.133**

Marchesini M., Gherli A., Montanaro A., Patrizi L., Sorrentino C., Pagliaro L., Rompietti C., Kitara S., Heit S., Olesen C. E., Møller J. V., Savi M., Bocchi L., Vilella L., Rizzi F., Baglione M., Rastelli G., Loiacono C., La Starza R., Mecucci C., Stegmaier K., Aversa F., Stilli D., Lund Winther A.M., Sportoletti P., Bubltz M., Dalby-Brown W., **Roti G.** Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell Chem Biol.* 2020 June18;27(6):678-697. E13. doi: 10.1016/j.chembiol.2020.04. **IF 8.116**

Mazzaschi G, Milanese G, Pagano P, Madeddu D, Gnetti L, Trentini F, Falco A, Frati C, Lorusso B, Lagrasta C, Minari R, Ampollini L, Silva M, Sverzellati N, Quaini F, **Roti G[#]**, Tiseo M[#]. Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC. *Lung Cancer.* 2020 Jun;144:30-39. # These authors contributed equally to this work **IF 5.894**

Mazzaschi, G., Bordi, P., Fioretzaki, R., Gnetti, L., Milanese, G., Tommasi, C., Bersanelli, M., **Roti, G.**, Scoditti, U., Leonardi, F., Quaini, F., Tiseo, M. Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma. *Clinical Lung Cancer* Volume 21, Issue 2, March 2020, Pages e65-e73 **IF 4.785**

Bertaggia I, De Stefano S, Di Lella F, **Roti G.** Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia. *Clin Case Rep.* 2019 Sep 18;7(11):2250-2251. **IF 0.532**

La Starza R, Cambò C, Pierini A, Bornhauser B, Montanaro A, Bourquin JP, Mecucci C, **Roti G.** Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. *JCO Precision Oncology*, 2019 Sep 20;3:PO.19.00172 **F 5.479**

Prezioso L, Manfra I, Bonomini S, Schifano C, Segreto R, Monti A, Sammarelli G, Todaro G, Sassi M, Bertaggia I, Pelagatti L, Cambò B, Spolzino A, Follini E, Re F, Crugnola M, Craviotto L, Russo F, Planteda C, **Roti G.** Giuliani N, Aversa F. Haploidentical hematopoietic stem cell transplantation in adults using the $\alpha\beta$ TCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells. *Bone Marrow Transplant.* 2019 Aug;54(Suppl 2):698-702 **IF 5.174**

Sorrentino C, Cuneo A, **Roti G.** Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies. *Mediterr J Hematol Infect Dis.* 2019 Jul 1;11(1):e2019037 **IF 2.430**

Follini, E.; Marchesini, M.; **Roti, G.** Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia. *Int. J. Mol. Sci.* 2019, 20, 3021. **IF 6.009**

Bandopadhyay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, Pages M, Balboni Iniguez A, Paoletta BR, Meng A, Sinai C, **Roti G.** Dharia NV, Creech A, Tanenbaum B, Khadka P, Tracy A, Tiv HL, Hong AL, Coy S, Rashid R, Lin JR, Cowley GS, Lam FC, Goodale A, Lee Y, Schoolcraft K, Vazquez F, Hahn WC, Tsherniak A, Bradner JE, Yaffe MB, Milde T, Pfister SM, Qi J, Schenone M, Carr SA, Ligon KL, Kieran MW, Santagata S, Olson JM, Gokhale PC, Jaffe JD, Root DE, Stegmaier K, Johannessen CM, Beroukhi R. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nat Commun.* 2019 Jun 3;10(1):2400. **IF 17.694**

Fernandez AGL, Crescenzi B, Pierini V, Di Battista V, Barba G, Pellanera F, Di Giacomo D, **Roti G.** Piazza R, Adelman ER, Figueroa ME, Mecucci C. A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes. *Leukemia.* **33**; 2481–2494(2019). **IF 12.883**

Iniguez AB, Alexe G, Wang EJ, **Roti G.** Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhyay P, Goodale A, Pantel S, Lee Y, Cheff DM, Hall MD, Guha R, Davis MI, Menard M,

Nasholm N, Weiss WA, Qi J, Beroukhim R, Piccioni F, Johannessen C, Stegmaier K. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer Cell*. 2018 Dec 10;34(6):922-938.e7. **IF 38.585**

Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, **Roti G**, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2018 Jul;65(7):e27062. **IF 3.167**

La Starza R, Messina M, Gianfelici V, Pierini V, Matteucci C, Pierini T, Limongi MZ, Vitale A, **Roti G**, Chiaretti S, Foà R, Mecucci C. High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. *Leukemia*. 2018 Aug;32(8):1807-1810. **IF 12.883**

La Starza R, Pierini T, Pastorino L, Albi E, Matteucci C, Crescenzi B, Sportoletti P, Covarelli P, Falzetti F, **Roti G**, Ascani S, Mecucci C. Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin. *Mol Cytogenet*. 2018 Jan 16;11:6. **IF 1.904**

Roti G, Qi J, Kitara S, Varca CA, Sanchez-Martin M, Kung AL, Ferrando AF, Bradner JE, Stegmaier K. Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. *J Exp Med*. 2018 Jan 2;215(1):197-216. **IF 17.579**

Baldoni S, Del Papa B, Aureli P, Dorillo E, De Falco F, Varasano E, Cecchini D, Zei T, Di Tommaso T, Rosati E, Gabriela A, **Roti G**, Stegmaier K, Di Ianni M, Falzetti F, Sportoletti P. Bepiridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. *International journal of cancer*. 2018 vol. 143, p. 958-970. **IF 7.316**

Antonello ZA, Hsu N, Bhasin M, **Roti G**, Joshi M, Van Hummelen P, Bryke CR, Nucera C. Combined therapy with BRAF^{V600E} and CDK4/6 inhibitors blocks clonal expansion of thyroid carcinoma with chromosome 5 aberrations and overcomes therapeutic resistance. *Oncotarget*. 2017 Sep 24;8(49):84743-84760. **IF 3.331**

Pikman Y, Alexe G, **Roti G**, Conway AS, Furman A, Lee ES, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. *Clin Cancer Res*. 2017 Feb 15;23(4):1012-1024. **IF 13.801**

Roti G and Stegmaier K. New Approaches to Target T-ALL. *Front Oncol*. 2014 Jul 8;4:170. **IF 5.738**

Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh B-C, Holson E, Florence F, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, **Roti G**, Kung AL, Bradner JE, Tolliday N, Stegmaier K. Selective HDAC/HDAC2 Inhibitors Induce Neuroblastoma Differentiation. *Chem Biol*. 2013; 20(5):713-25. **IF 5.915**

- As featured in Science News: New Screening Approach Uncovers Potential Alternative Drug Therapies for Neuroblastoma. May 2013

Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Perrimon N, Pear WS, Kung AL, Blacklow SC, Aster JC, Stegmaier K. Complementary genomic screens identify SERCA as a therapeutic target in *notch1* mutated cancer. *Cancer Cell*. 2013 Mar 18;23(3):390-405. **IF 38.585**

- As featured in Cancer Cell. 2013 Mar 18;23(3):267-9. Ilagan MX, Kopan R. Selective blockade of transport via SERCA inhibition: the answer for oncogenic forms of Notch?
- As featured in Nat Med. 2013 May;19(5):546. Boettner B. Cancer therapy: A Notch further with SERCA.
- As featured in Cancer Res April 1, 2013 73; 2023

Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, Kakoza RM, Chow KT, Ross L, Alexe G, Tolliday N, Inguilizian H, Galinsky I, Stone RM, DeAngelo DJ, **Roti G**, Aster JC, Hahn WC, Kung AL, Stegmaier K. The intersection of genetic and chemical genomic screens identifies GSK-3 α as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar 1;122(3):935-47. **IF 19.456**

Roti G and Stegmaier K. Targeting NOTCH1 in Hematopoietic Malignancy. Crit Rev Oncog. 2011;16(1-2):103-15. **IF 1.453**

Roti G and Stegmaier K. Genetic and Proteomic Approaches to Identify Cancer Drug Targets. Br J Cancer. 2012 Jan 17;106(2):254-61. **IF 7.64**

Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleyrier F, L'heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, **Roti G**, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE. Characterization of notch1 antibodies that inhibit signaling of both normal and mutated notch1 receptors. PLoS One. 2010 Feb 8;5(2):e9094. **IF 3.240**

Roti G[#], Corsello SM[#], Ross KN, Chow KT, Galinsky I, Stone RM, DeAngelo DJ, Kung AL, Golub TR, Stegmaier K. Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11;113(24):6193-205. # These authors contributed equally to this work. **IF 22.113**

Matteucci C, Bracci M, Barba G, Carbonari M, Casato M, Visentini M, Pulsoni A, Varasano E, **Roti G**, La Starza R, Crescenzi B, Martelli MF, Fiorilli M, Mecucci C. Different genomic imbalances in low- and high-grade HCV-related lymphomas. Leukemia. 2008 Jan;22(1):219-22. **IF 12.883**

La Starza R, Rosati R, **Roti G**, Gorello P, Bardi A, Crescenzi B, Pierini V, Calabrese O, Baens M, Folens C, Cools J, Marynen P, Martelli MF, Mecucci C, Cuneo A. A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome. Leukemia 2007 Apr;21(4):830-3. **IF 12.883**

Rosati R, La Starza R, Barba G, Gorello P, Pierini V, Matteucci C, **Roti G**, Crescenzi B, Aloisi T, Aversa F, Martelli MF, Mecucci C. Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. Haematologica. 2007 Feb;92(2):232-5. **IF 11.047**

Sciaccaluga M, Gianfranceschi GL, Rocco S, Germano G, **Roti G**, Gorello P, La Starza R, Castigli E. Constitutive phosphorylation of Janus Kinase 2 in GL 15 glioblastoma derived human cell line. Oncol Rep. 2007 Jan 17(1):17-23. **IF 4.136**

Roti G, La Starza R, Ballanti S, Crescenzi B, Romoli S, Foà R, Tartaglia M, Aversa F, Martelli MF, Mecucci C. Acute lymphoblastic leukemia in Noonan syndrome. British Journal of Hematology 2006, 133:448-450. **IF 6.998**

Roti G, Rosati R, Bonasso R, Gorello P, Diverio D, Martelli MF, Falini B, Mecucci C. DHPLC: a valid approach for identifying NPM1 mutations in acute myeloid leukaemia. Journal of Molecular Diagnostics, 2006, 8: 254-259. **IF 5.568**

Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, **Roti G**, Rosati R, Martelli MF, Diverio D, Lo Coco FL, Biondi A, Saglio G, Mecucci C, Falini B. Quantitative assessment of minimal residual disease in acute myeloid leukaemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;6: 1103:8. **IF 12.883**

Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E., Pallotta MT, Diverio D, Nicoletta I, Pacini R, Tabarrini A, Verducci Galletti B, Mannucci R, **Roti G**, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo Coco F, Saglio G, Pelicci PG, Martelli MF, Mecucci C. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.. Blood 2006; 108(6):1999-2005. **IF 22.113**

Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, **Roti G**, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haerlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, and Nicoletti I. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+AML. Blood 2006; 20:1103-8. **IF 22.113**

Bolli N, Galimberti S, Martelli M.P, Tabarrini A, **Roti G**, Mecucci C, Martelli MF, Petrini M, Falini B. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncology, 2006 Apr;7(4):350-2. **IF 41.316**

Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica. 2005 Aug; 90(8):1139-41. **IF 11.047**

Colla S, **Roti G**, Rizzoli V, Giuliani N. Angiopoietins expression by human myeloma cells. Haematologica. 2003 Jun;88(6). **IF 11.047**

Giuliani N, Caramatti C, **Roti G**, Geata A, Colla S, Bonomini S, Hojden M, La Monica S, Sammarelli G, Lazzaretti M, Cravio L, Mangoni L, Rizzoli V. Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol. 2003 May 1;21(9):1887-8. **IF 50.717**

Giuliani N, Colla S, Lazzaretti M, Sala R, **Roti G**, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 2003 Jul 15;102(2):638-45. **IF 22.113**

ABSTRACT/MEETING

Montanaro A., Monica G., D'Antonio A., Zamponi R., Sammarelli G., Todaro G., La Starza R., Mecucci C., Giaimo M., Gherli A., Vento F., Lorusso B., Simoncini E., Pagliaro L., Jimenez C.R., Quaini F., **Roti G**. Targeting the atypical protein kinase WNK1 in TAL1-related T-cell acute lymphoblastic leukemia. S105 Oral communication 31st Congress of the European Hematology Association, 2026 Stockholm, June 11-14.

Montanaro A., Monica G., D'Antonio A., Zamponi R., Sammarelli G., Todaro G., La Starza R., Mecucci C., Giaimo M., Gherli A., Vento F., Lorusso B., Simoncini E., Pagliaro L., Jimenez C.R., Quaini F., **Roti G**. L'identificazione della proteina chinasi atipica WNK1 come target farmacologico nelle leucemie linfoblastiche acute a cellule T correlate a TAL1. Oral communication XIX Congresso SIES, 2026 Firenze, March 04-06.

Simoncini E., Zamponi R., Montanaro A., Poldi Allay patarino R.M., Vento F., Gherli A., Marinoni V., Lorusso B., Rosati R., Monica G., Castelli R., Andolfo A., Braccia C., Lodola A., **Roti G**. L'inibizione

dell'asse PA2G4-NPM1 induce stress nucleolare nelle AML con mutazione di NPM1. Oral communication XIX Congresso SIES, 2026 Firenze, March 04-06.

Giaimo M., Cambò B., Pagliaro L., Zamponi R., Rosati R., Forte D., Gherli A., Crugnola M., Prezioso L., Rinaldi A., Pessina A., Bonomini S., Sammarelli G., Montanaro A., Pasini F., Polanco I.S., Ocladlikova D., Ferrari A., salvisi C., Spedaluzzi A., Paganelli A., Tosi P., Tieghi A., Vallisa D., Cuneo A., Lanza F., Simonelli G., Martinelli G., Curti A., **Roti G.** Approccio integrato di farmacogenomica e caratterizzazione del microambiente nelle leucemie ad alto rischio. Oral Communication. XIX SIES, 2026 Firenze, March 04-06.

Simoncini E., Zamponi R., Montanaro A., Poldi Allay Patarino R.M., Vento F., Gherli A., Lorusso B., Rosati R., Monica G., Sarcone L., Castelli R., Karnchanapandh K., Mor M., Martelli M.P., Lodola A., **Roti G.** Disrupting the PA2G4-NPM1 axis induces nucleolar stress in NPM1c AML. Poster presentation 67th American Society of Hematology Meeting, Orlando, Florida, December 6-9, 2025.

Pagliaro L., Giaimo M.T., Rosati R., Zamponi R., Carnevali D., Cambò B., Bardelli V., Tragni K., Montanaro A., Messina M., Piciocchi A., Marsili G., Crea E., Ciceri F., Chiaretti S., Papayannidis C., Piccini M., Rambaldi A., Sica S., Zappasodi P., Rinaldi A., Prezioso L., Mecucci C., La Starza R., **Roti G.** Early Results from the GIMEMA ALL2720 Trial: Chemogenomic Strategies In Relapsed/ R.Refractory T-ALL And ETP-ALL. *Discussed Poster Presentation*. ID: DP087. 52° Congresso Nazionale SIE 2025-Milan, Italy, October 20-22.

Messina M., Marsili G., Pagliaro L., Giaimo M., Bardelli V., Arniani S., Pierini V., Crea E., Orlando S., Rughini A., Sargentini V., Di Donato L., Piciocchi A., Fazi P., Vignetti M., La Starza R., Roti G., Mecucci C. eposter ID: P054. 52° congresso Nazionale SIE 2025, October 20-22, Milan, Italy.

Pagliaro L., Giaimo M.T., Rosati R., Zamponi R., Carnevali D., Cambò B., Bardelli V., Tragni K., Montanaro A., Messina M., Piciocchi A., Marsili G., Crea E., Ciceri F., Chiaretti S., Papayannidis C., Piccini M., Rambaldi A., Sica S., Zappasodi P., La Starza R., Mecucci C., **Roti G.** Advancing chemogenomic strategies for functional precision medicine in relapsed/refractory T-ALL and ETP-ALL: preliminary results of the GIMEMA ALL2720 trial. EHA Hybrid Congress, Milano, June 12-15, 2025. *Hemasphere* 2024, Vol. 8 (S1). Doi. 10.1002/hem3.104

Monica G., Montanaro A., D'Antuono A., Zamponi R., Andrei P., Sammarelli G., Todaro G., La Starza R., Mecucci C., Giaimo M.T., Gherli A., Vento F., Lorusso B., Simoncini E., Pagliaro L., Jimenez C.J., Quaini F., **Roti G.** Identification of WNK1 as a druggable target in TAL-related T.Cell Acute Lymphoblastic Leukemia. Oral presentation. 4th Translational Research Conference Acute Lymphoblastic Leukemia, Malahide (Dublin), May 22-24, 2025.

Pagliaro L., Van Sttenberge H., T'Sas S., Zamponi R., Lintermans B., Sleekx W., Giaimo M.T., **Roti G.**, Van Vlierberghe P., Goossens S., pieters T. A functional precision medicine approach in preclinical mantle cell lymphoma models identifies selected target therapies for drug clinical repurposing. ESH 4th How to diagnose and treat lymphoma, Stockholm, Nov 1-3, 2024.

Pagliaro L., Giaimo M.T., Zamponi R., Tragni K., Dalla Tor L.M., Montanaro A., Cambo B., Messina M., Bardelli V., La Starza R., **Roti G.** Functional omics to guide a precision medicine approach in high- risk T-cell acute lymphoblastic leukemia. EHA-SfPM 2024 Precision Medicine Meeting, Copenhagen, September 26-27, 2024.

Pagliaro L., Van Steenberge H., T'sas S., Zamponi R., Lintermans B., Slleckx W., **Roti G.**, Van Vlierberghe P., Goossens S., Pieters T. Drug profiling in a preclinical murine mantle cell lymphoma mouse model identifies novel vulnerabilities. EHA Hybrid Congress; Madrid, June 13-16, 2024.

Simoncini E., Marchesini M., Gherli A., Zamponi R., Moron Dalla Tor L., Montanaro A., Vento F., Pagliaro L., Giaimo M., Cambò C., La Starza R., Mecucci C., Quaini F., Colla S., Castelli R., Lodola A., **Roti G.** Uncovering the potential of the PA2G4-MYC axis as a target in 3q26 acute myeloid leukemia. Oral presentation. EHA Hybrid Congress 2024, 13-16 June, Madrid.

Simoncini E., Marchesini M., Gherli A., Moron Dalla Tor L., Montanaro A., Vento F., Pagliaro L., Zamponi R., La Starza R., Mecucci C., Quaini F., Colla S., Roti G. The intersection of proteogenomic approaches identifies PA2G4 as a new target in 3q26 AML. Oral presentation C37 XVIII Congresso Nazionale SIES 2024, March 7-9, Firenze. Haematologica, March 2024, vol. 30 (S1).

Giaimo M., Pagliaro L., Zamponi R., Moron Dalla Tor L., Tragni K., Montanaro A., Cambò B., Messina M., Bardelli V., La Starza R., Mecucci C., Roti G. Functional omics in high-risk T-cell acute lymphoblastic leukemia. Oral communication C01. XVIII Congresso Nazionale SIES 2024, March 7-9, Firenze. Haematologica, March 2024, vol. 30 (S1).

Nasuto M.I., Todaro G., Cambò B., sammarelli G., Arienzo F., Giordano C., Giaimo M., Rinaldi A., Prezioso L., Bonomini S., Segreto R., Craviotto L., Roti G. Myeloid neoplasms with ALK rearrangement, a rare entity with aggressive course: a new case report. Poster P016. XVIII Congresso Nazionale SIES 2024, March 7-9, Firenze. Haematologica, March 2024, vol. 109 (S1).

Cerretani E., Pagliaro L., Vento F., Montanaro A., Moron Dalla Tor L., Simoncini E., Giaimo M., Gherli A., Zamponi R., D'Antuono A., Tartaglione I., Lorusso B., Quaini F., Rigolin GM., Cuneo A., **Roti G.** Specific antitumor activity of the new SERCA inhibitor CAD204520 in lymphoproliferative disorders with NOTCH1 PEST domain mutation. 3rd Translational Research Conference on CLL. Vienna, March 8-10, 2024.

Montanaro A., D'Antuono A., Moron Dalla Tor L., Andrei P., Cavazzini F., Cerretani E., Vento F., Simoncini E., Gherli A., Zamponi R., Lorusso B., Todaro G., Giaimo M.T., La Starza R., Mecucci C., Sammarelli G., Marchesini M., Pagliaro L., **Roti G.** The atypical protein kinase WNK1 controls leukemia progression in TAL/LMO T-cell acute lymphoblastic leukemia. 65th American Society of Hematology Meeting, San Diego, CA. December 9-12, 2023. Blood 2024, Vol. 142 (S1), doi: 10.1182/blood-2023-188375.

Giaimo M., Cambò B., Crugnola M., Prezioso L., Rinaldi A., Bonomini S., Segreto R., Sammarelli G., Craviotto L., Roti G. Diagnosi e trattamento della trombocitopenia amegacariocitica acquisita: esperienza di un singolo centro. Poster P186. 50° Congresso Nazionale SIE 2023, 23-25 ottobre, Roma.

Montanaro A., D'Antuono A., Moron Dalla Tor L., Andrei P., Ciringione A., Cerretani E., Vento F., Pagliaro L., Gherli A., Lorusso B., Simoncini E., Zamponi R., Salvatori C., Todaro G., La Starza R., Mecucci C., Sammarelli G., Marchesini M., **Roti G.** Identification of the atypical protein kinase WNK1 as a new target in T-cell acute lymphoblastic leukemia. Poster presentation. 64th ASH Annual Meeting and Exposition; New Orleans, LA. December 10-13, 2022. Blood 2022 140, Supplement 1: 3130-3131, doi:10.1182/blood-2022-163069.

Marchesini M., Gherli A., Simoncini S., Montanaro A., Thongon N., Pagliaro L., Vento F., Moron Dalla Tor L., Liverani C., Zamponi R., Follini E., Cambò B., Lorusso B., La Starza R., Cuneo A., Mecucci C., Colla S., Quaini F., **Roti G.** Orthogonal proteogenomic approaches identify the druggable PA2G4-MYC Axis in 3q26 AML. Oral communication. 64th ASH Annual Meeting and Exposition; New Orleans, LA. December 10-13, 2022. Blood 2022 140 Supplement 1: 673-674, doi: 10.1182/blood-2022-158990.

Pagliaro L., Moron Dalla Tor L., Vento F., Andrei P., Monica L., Kleissle S., Neuenschwander M., Gherli A., Cerretani E., D'Antuono A., Simoncini E., Montanaro A., **Roti G.** A chemotranscriptomic screening identifies the reversal of glucocorticoid resistance in NOTCH1 mutated T-ALL. 26th Congress of the

European Hematology Association (poster presentation) 2022, June 9-12, Vien. Hemasphere 6: 236-237, June 2022.

Pagliaro L., Tragni K., Roti G. From genomics to chemogenomics in T cell acute lymphoblastic leukemia. 48° Congresso nazionale SIE e 16° Congresso Nazionale SIES 2021, October 24-27, Haematologica 2021, Vol. 106, S1.

Rinaldi A., Cambò B., Prezioso L., Giaimo M.T., Pagliaro L., Dalla Palma A.B., Sammarelli G., La Starza R., Vallisa D., **Roti G.** t(10;11)(p13;p14-21) PICALM-MLLT10 acute leukemia: characterization of two cases with different phenotypic presentation. 48° Congresso nazionale SIE e 16° Congresso Nazionale SIES 2021, October 24-27. Haematologica 2022, Vol. 106, (S3), 132-132.

Marchesini M., Gherli A., Montanaro A., Sorrentino C., Pagliaro L., Rompietti C., Rizzi F., Stilli D., Lund Winther A.M., La Starza C., Mecucci C., Sportoletti P., Bublit M., Dalby-Brown W., **Roti G.** Inibizione selettiva delle mutazioni di NOTCH1 attraverso il nuovo inibitore di SERCA CAD204520. Oral communication. 48° Congresso nazionale SIE e 16° Congresso nazionale SIES 2021, October 24-27. Haematologica, Oct 2020, Vol. 105 (S2), pp. S46-S47.

Pagliaro L., Moron Dalla Tor L., Monica L., Andrei P., Vento F., Simoncini E., Kleissle S., Neuenschwander M., Gherli A., Cerretani E., D'Antuono A., Montanaro A., **Roti G.** SERCA modulation counteracts glucocorticoid resistance in T-ALL. 17°Congresso Nazionale SIES 2022, March 31, April 1-2, Roma. Haematologica 2022, vol. 107 (S1), p. 19-19.

Montanaro A., Cerretani E., Kitara S., Marchesini M., Rompietti C., Pagliaro L., Gherli A., Lorusso B., Minichillo ML., La Starza R., Mecucci C., Xiong Y, Jin J., Quani F., Knoechel B., Sportoletti P, Stegmaier K., **Roti G.** *EHMT2/G9A* Drives the Epigenetic Regulation Of Glucose Metabolism in T-Cell Acute Lymphoblastic Leukemia. 25th Congress of the European Hematology Association Virtual June 9-17, 2021. Hemasphere 2021, vol. 5 (S2), pp. 546-547.

Marchesini M, Gherli A, Montanaro A, Kitara S, Sorrentino C, Pagliaro L, Kitara S, Rompietti C, Rizzi F, Stilli S, Stegmaier K, Lund Winter AM, Sportoletti P, Bublit M, Dalby-Brown W, **Roti G.** Selective blockade of oncogenic NOTCH1 with the new SERCA inhibitor CA204520. 24th Congress of the European Hematology Association, Virtual June 11-, 2020. Hemasphere 2020, vol. 4 (S1), p. 7.

Marchesini M, Gherli A, Montanaro A, Kitara S, Sorrentino C, Pagliaro L, Rompietti C, Lund Winter AM, Stilli D, Stegmaier K, Rizzi F, Sportoletti P, Dalby-Brown W, **Roti G.** Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520. 61st American Society of Hematology Meeting, Orlando, FL December 8-11, 2019. Blood 2019, vol.134 (S1), p. 31.

Marchesini, M; Gherli, A; Winter, AML; Kitara, S; Montanaro, A; Rompietti, C; Sorrentino, C; Stilli, D; Rizzi, F; Pagliaro, L; Stegmaier, K; Dalby-Brown, W; **Roti, G.** Selective blockade of oncogenic NOTCH1 with the new SERCA inhibitor CAD204520 in T-cell acute lymphoblastic leukemia. International Conference on Molecular targets and Therapeutics, 2019, October 26-30, Boston M.A. Molecular cancer therapeutics, Dec 2019, vol. 18 (12_supplement), B113.

Mazzaschi, G; Quaini, F; Milanese, G; Gnetti, L; Bocchialini, G; Ampollini, L; Minari, R; Silva, M; Sverzellati, N; **Roti, G**; Tiseo, M. Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC. ANNALS OF ONCOLOGY. OCT 2019. Volume: 30 Supplement: 5 Pages: 797-797 . Conference: 44th Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Barcelona, SPAIN Date: September 27-October 01, 2019. Annals of Oncology 2019, vol. 30 (S5), 1982PD.

Mazzaschi, G; Quaini, F; Milanese, G; Madeddu, D; Bocchialini, G; Ampollini, L; Gnetti, L; Lagrasta, C; Silva, M; **Roti, G**; Sverzellati, N; Tiseo, M. Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC. Conference: European Lung Cancer Congress (ELCC) Location: Geneva, Switzerland Date: April 10-13, 2019. *Annals of Oncology*, Apr 2019, vol. 30 (S2). doi: 10.1093/annonc/mdz072.

Marchesini M, Gherli A, Lund Winter AM, Patrizi L, Kitara S, Montanaro A, Rompietti C, Sorrentino C, Stilli D, Rizzi F, Loiacono C, Pagliaro L, La Starza R, Mecucci C, Aversa F, Sportoletti P, Dalby-Brown W, **Roti G**. Targeting oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia with a new selective serca inhibitor CAD204520. 24th Congress of the European Hematology Association Amsterdam, Netherlands, June 13-16, 2019. *Hemasphere*, June 2019, vol. 3 (S1), p. 31.

Mazzaschi, G; Pagano, P; Milanese, G; Madeddu, D; Falco, A; Armani, G; Bocchialini, G; Marturano, D; Ampollini, L; Lorusso, B; Lagrasta, C; Sverzellati, N; Silva, M; Tiseo, M; Quaini, F; **Roti, G**. Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC. ESMO Immuno-Oncology Congress Location: Geneva, Switzerland Dec 13-16, 2018. *Annals of Oncology*, 2018, vol. 29 (S10). doi: 10.1093/annonc/mdy493.

Cambò, B; La Starza, R; Patrizi, L; Rastelli, G; Baglione, M; Follini, E; Bertaggia, I; Sammarelli, G; Bonomini, S; Pierini, T; Bornhauser, B; Bourquin, JP; Mecucci, C; Aversa, F; **Roti, G**. Overcome resistance to chemotherapy by using drug sensitivity and resistance profiling in T-ALL. 15th Congress of the Italian-Society-of-Experimental-Hematology, Rimini, Italy Oct 17 2018. *Haematologica* 2018, vol. 103 (S3), p. 73.

Montanaro A., Kitara S., Fioretzaki R., Su A., Gherli A., Jin J., Quani F., Aversa F., Knoechel B., Stegmaier K., **Roti G**. Targeting G9A/EHMT2 in T-cell acute lymphoblastic leukemia. 23rd Congress of the European Hematology Association Stockholm, Sweden, June 14-17, 2018. *Hemasphere* 2018, vol. 2 (S1), p. 36.

Montanaro, A; Kitara, S; Fioretzaki, R; Su, A; Gherli, A; Marchesini, M; Jin, J; Quani, F; Aversa, F; Knoechel, B; Stegmaier, K; **Roti, G**. The identification of G9A/EHMT2 reveals a novel interaction between epigenetics and metabolism in T-cell acute lymphoblastic leukemia-15th Congress of the Italian-Society-of-Experimental-Hematology Rimini, Italy Oct 17 2018. *Haematologica* 2018, vol. 103 (S3), p. S56.

Kitara, S; Su, A; Deluca, C; Aversa, F; Knoechel, B; Jin, J; Stegmaier, K; **Roti, G**. Identification of EHMT2 As a New Target in T-Cell Acute Lymphoblastic Leukemia. 59th American Society of Hematology Meeting Atlanta, Georgia, 2017. *Blood* 2017, Dec. 7, vol. 130 (S1), p. 2548.

Bandopadhyay, P; Paoletta, B; O'Rourke, R; Ho, P; Greenwald, N; Sharpira, O; Pantel, S; Bagul, M; Tracy, A; **Roti, G**; Balboni, A; Vazquez, F; Ligon, K; Piccioni, F; Stegmaier, K; Johannessen, C; Beroukhim, R - Resistance mechanisms to BET-bromodomain inhibition in myc-amplified medulloblastoma 4th Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research Location: New York, NY Date: JUN 15-16, 2017. *Neuro Oncology*, June 2017, vol. 19 (S4), pp. 54-55.

Roti G, Qi J, Kitara S, Su A, Varca A, Sanchez-Martin M, Kung A, Adolfo AA, Bradner J, Stegmaier K. Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. 58th American Society of Hematology Meeting, San Diego, CA December 3-6, 2016. *Blood*, Dec. 2016, vol. 128, issue 22, p. 889.

Sportoletti P, Baldoni S, Del Papa B, Aureli P, Dorillo E, Varasano E, Cecchini D, Zei T, Di Tommaso A, De Falco F, Plebani S, Amico V, **Roti G**, Stegmaier K, Rosati E, Falini B, Di Ianni M, Falzetti F. In vitro and in vivo antileukemic activity of bepridil in chronic lymphocytic leukemia is associated with inhibition of the NOTCH1 pathway. 20th Congress of the European Hematology Association, Vienna June, 11-14 2015. *Haematologica* 2015, vol. 100 (S1), p. 11.

Roti G, Qi J, Su A, Varca A, Aster JC, Bradner J, Stegmaier K. Selectively targeting mutated NOTCH1 with the folate-thapsigargin derivative JQ-FT. 56th American Society of Hematology Meeting, San Francisco 6-9 December 2014. *Blood*, Dec. 2014, vol. 124, issue 21, p. 2158.

Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Perrimon N, Kung AL, Pear WS, MD, Blacklow S, Aster JC, Stegmaier K. Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies. 53th American Society of Hematology Meeting, San Diego 10-13 December 2011. *Blood*, Nov. 2011, vol. 118, issue 21, p. 555.

Roti G, Ross KN, Blacklow SC, Aster JC, Stegmaier K. Expression-based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL. 51st American Society of Hematology Meeting, New Orleans 4-8 December 2009. *Blood*, Nov. 2008, vol. 114, issue 22, p. 366.

Roti G, Ross KN, Mecucci C, Ferrando AA, Aster JC, Stegmaier K. Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL. 50th American Society of Hematology Meeting, San Francisco 6-9 December 2008. *Blood*, Nov. 2008, vol. 112, issue 11, p. 200.

Roti G, Ross KN, Mecucci C, Aster JC, Stegmaier K. Modulating Notch1 with Signature-based Small Molecule Library Screening. 13th Congress of the European Hematology Association, Copenhagen 12-15 June 2008

Matteucci C, Bracci M, Barba G, Carbonari M, Casato M, Pulsoni A, **Roti G**, La Starza R, Crescenzi B, Martelli ME, Fiorilli M, Mecucci C. Genetic pathways in low-and high-grade HCV-related lymphomas are different. 12th Congress of the European Hematology Association. Vienna, Austria, 07-10 June, 2007.

La Starza R, **Roti G**, Brandimarte L, Varasano E, Arcioni F, Pierini A, Crescenzi B, Diverio D, Guglielmini G, Martelli MF, Aventin A, Mecucci C (2007). NPM1 haploinsufficiency in MDS/AML with del(5q)/monosomy 5. 12th Congress of the European Hematology Association. Vienna, Austria, 07-10 June, 2007.

Roti G, La Starza R, Bury L, Pecoraro V, Crescenzi B, Barba G, Gambacorti-passerini C, Pogliani E, Arcioni F, Pierini A, Martelli MF, Mecucci C. Mutational analysis of JAK2 VAL617PHE in a new series of chronic myelomonocytic leukemia and related atypical myeloproliferative disorders. *Haematologica* 2006;91: supplement no. 3. Presented 9th Congress of the Italian-Society-of-Experimental-Hematology Napoli, Italy, September 20-22, 2006.

Roti G, R. La Starza, B. Crescenzi, S. Romoli, S. Ballanti¹, R. Foà, M. Tartaglia, M.F. Martelli, C. Mecucci. Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome. *Haematologica* 2006;91: supplement no. 1. P429 Presented at 10th Congress of the European Hematology Association Stockholm, Sweden, June 2-5, 2006.

Roti G, R. Rosati, R. Bonasso, P. Gorello¹, D. Diverio, A. Aventin, M.F. Martelli¹, B. Falini, C. Mecucci. DHPLC analysis of *NPM1* mutations in adult primary AML. *Haematologica* 2006;91: supplement no. 1. P046 Presented at 10th Congress of the European Hematology Association Stockholm, Sweden, June 2-5, 2006.

Saglio G., Gorello P., Cazzaniga G., Gottardi E., Dell'oro M., Rosati R., **Roti G.**, Alberti F., Diverio D., Martelli M.F., Lo Coco F., Biondi A., Falini B., Mecucci C. Quantitative detection of NPM1 mutations as marker of minimal residual disease (MRD) in the large majority of AML with normal karyotype. Presented at the 47th American Society of Hematology Meeting, Atlanta 10-13 December 2005.

Falini B., Bolli N., Schan J., Martelli M.P., Nicoletti I., Liso A., Pasqualucci L., Rosati R., **Roti G.**, Diverio D., Mannucci R., Cazzaniga G., Biondi A., Saglio G., Pane F., Lo Coco F., Pelicci P., Martelli M.F., Gu W., Mecucci C. Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML). American Hematology Association 47th Meeting, Atlanta 10-13 December 2005

Rosati R, Gorello P, Bonasso R, La Starza R, **Roti G**, Cazzaniga G, Crescenzi B, Biondi A, Lo Coco F, Pession A, Diverio D, Martelli MF, Falini B, Mecucci C. *NPM1* gene mutations in acute myeloid leukemia. *Haematologica* 2005;90: supplement no. 3. P459 Presented at 40th Congress of the Italian Society of Hematology Bergamo, July 3-6.

La Starza R, **Roti G**, Crescenzi B, Beacci D, Perfetti P, Romoli S, Tartaglia M, Fumagalli M, Martelli MF, Gambacorti-passerini C, Pogliani E, Mecucci C. Molecular cytogenetic studies of myelodysplastic/myeloproliferative disease. *Haematologica* 2005;90: supplement no. 3. P033 Presented at 40th Congress of the Italian Society of Hematology Bergamo, July 3-6.

Roti G, Rosati R, Bonasso R, Gorello P, Diverio D, Martelli MF, Falini B, Mecucci C. Denaturing high performance liquid chromatography analysis of npm1 mutations in adult primary acute myeloid leukemia. *Haematologica* 2005;90: supplement no. 3. S002 Presented at 40th Congress of the Italian Society of Hematology Bergamo, July 3-6.

Roti G, Crescenzi B, La Starza R, Ballanti S, Piattoni S, Gottardi E, Fava M, Saglio G, Martelli MF, Mecucci C. bcr-abl1/e6a2 translocation is sensible to imatinib mesylate. *Haematologica* 2004;89: supplement no. 6. PO-058 Presented at 7th Congress of the Italian-Society-of-Experimental-Hematology Pavia, September 14-16, 2004.

Giuliani N, Colla S, Lazzaretti M, Roberto, Sala R, **Roti G**, Mancini C, Bonomini S, Lunghi P, Hojden, Genestretti G, Svaldi M, Coser P, Pier Paolo, Fattori P, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Lina Mangoni L, Rizzoli V. Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis. *Haematologica* 2003;88:4 supplement no. 1. N144 Presented at 9th International Workshop on Multiple Myeloma.

Giuliani N, Colla S, **Roti G**, Bonomini S, Hojden M, Sammarelli G, Morandi F, Bataille R, Rizzoli R. Il-7 is induced by il-6 in human myeloma cells: role in multiple myeloma. *Haematologica* 2003;88:4 supplement no. 1. N110 Presented at 9th International Workshop on Multiple Myeloma.

Giuliani N, Lunghi P, Morandi F, Hojden M, Bonomini S, Colla S, **Roti G**, Bataille R, Rizzoli R, Bonati A. Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition. *Haematologica* 2003;88:4 supplement no. 1. N109 Presented at 9th International Workshop on Multiple Myeloma.

Rizzoli V, Sammarelli G, Lazzaretti M, La Monica, S, **Roti G**, Hojden M, Bonomini S, Sala R, Mangoni L, Genestretti C, Fattori P, Giuliani N. Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. . Presented at the American Hematology Association 44th Meeting, Philadelphia 6-10 December 2002.

Lunghi P, Giuliani N, La Monica S, Bonomini S, Hojden M, Colla S, **Roti G**, Ridolo E, Sammarelli G, Pinelli S, Bataille R, Rizzoli V, Bonati A. Down-modulation of ERK protein kinase activity inhibits vascular

endothelial growth factor (VEGF) secretion by human myeloma cell lines. Presented at the American Hematology Association 44th Meeting, Philadelphia 6-10 December 2002.

Giuliani N, Colla S, La Monica S, **Roti G**, Bonomini S, Hojden M, Sammarelli G, Bataille R, Rizzoli V (2002). Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6. Presented at the American Hematology Association 44th Meeting, Philadelphia 6-10 December 2002.

Giuliani N, **Roti G**, Colla S, La Monica S, Bonomini S, Hojden M, Sammarelli G, Bataille R, Rizzoli V. Osteopontin is produced by human multiple myeloma cells. Presented at the American Hematology Association 44th Meeting, Philadelphia 6-10 December 2002.

Colla S, La Monica S, **Roti G**, Sammarelli G, Bonomini S, Hojden M, Bataille R, Rizzoli V, Giuliani N. Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma. Presented at the American Hematology Association 44th Meeting, Philadelphia 6-10 December 2002.

Giuliani N, Caramatti C, Gaeta A, **Roti G**, Colla S, Hojden M, Sammarelli G, La Monica S, Craviotto L, Rizzoli V. Multiple Myeloma Patient with unusual extramedullary involvement. Haematologica 2002;87: supplement 1 to no. 9. N087. Presented at VII Congress of the Italian Society of Experimental Hematology.

SCIENCE OUTREACH

Leukemia Research Foundation: <https://www.youtube.com/watch?v=K63zC4P8NYY>

Il Sole 24 ore: https://www.ifabfoundation.org/wp-content/uploads/2023/04/Oncologia_Big_data_e_Intelligenza_artificiale_a_servizio_delle_cure_personalizzate_Sanita24_-_Il_Sole_24_Ore_1.pdf

La Repubblica:

https://parma.bologna.repubblica.it/cronaca/2022/07/19/news/medicina_personalizzata_in_oncologia_36_milioni_dal_ministero_alluniversita_di_parma-358375624/

La Repubblica: https://www.repubblica.it/salute/medicina-e-ricerca/2019/12/09/news/matteo_chiara_e_gli_altri_la_carica_dei_ricercatori_italiani_premiati_negli_usa-242956855/

La Repubblica:

https://parma.repubblica.it/cronaca/2019/12/10/news/leucemi_e_tumori_premio_dell_american_society_hematology_ricercatore_dell_universita_di_parma-243080955/

Gazzetta di Reggio: <https://gazzettadireggio.gelocal.it/reggio/cronaca/2019/09/15/news/il-ricercatore-che-combatte-le-leucemie-premiato-dal-presidente-mattarella-1.37469748>

AIRC: Italian Association for cancer research: <http://www.inviaggioconlaricerca.airc.it/archivio/?ID=1237>

La Repubblica: https://www.repubblica.it/salute/medicina-e-ricerca/2018/06/11/news/ematologia_un_ricercatore_italiano_vince_il_gilead_international_scholar_award_-198734304/

1st CORBEL project: <https://www.corbel-project.eu/1st-open-call.html>

Radio RAI (National broadcast): <https://www.raiplayradio.it/audio/2018/06/6-SU-RADIO1-ce3bfb20-964c-4efa-b804-db4102c5abb9.html>

Gazzetta di Parma: https://www.gazzettadiparma.it/archivio-bozze/2017/01/27/news/i_cervelli_in_fuga_li_riportiamo_a_casa-76662/

Technology for Health: <https://www.tecnicaospedaliera.it/ematologia-luniversita-di-parma-selezionata-per-il-trth/>

Umberto Veronesi Foundation: <https://www.fondazioneveronesi.it/ricerca/i-nostri-ricercatori/giovanni-roti>

Accademia dei Lincei: http://www.lincai.it/files/convegni/Premiati_2010.pdf

Corriere della Sera Brescia (16/09/2014)

Leukemia and Lymphoma Society: [https://www.blackstone.com/media/press-releases/article/blackstone-employees-race-to-raise-over-\\$1-2-million-for-the-leukemia-and-lymphoma-society](https://www.blackstone.com/media/press-releases/article/blackstone-employees-race-to-raise-over-$1-2-million-for-the-leukemia-and-lymphoma-society)

Quotidiano Sanità: <https://www.quotidianosanita.it/allegati/allegato4914251.pdf>

The Hematologist: <https://www.hematology.org/Thehematologist/News/6409.aspx>

ISSNAF: <https://www.issnaf.org/awards-finalists.html>

EurekAlert! AAAS: https://www.eurekalert.org/pub_releases/2007-02/asoh-pbc022707.php

Parma 10/06/2025

